These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491 [TBL] [Abstract][Full Text] [Related]
10. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295 [TBL] [Abstract][Full Text] [Related]
11. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962 [TBL] [Abstract][Full Text] [Related]
12. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study. De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525 [TBL] [Abstract][Full Text] [Related]
13. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114 [TBL] [Abstract][Full Text] [Related]
14. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921 [TBL] [Abstract][Full Text] [Related]
16. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432 [TBL] [Abstract][Full Text] [Related]
18. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815 [TBL] [Abstract][Full Text] [Related]
19. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401 [TBL] [Abstract][Full Text] [Related]
20. Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom. Wang L; Howlett S; Essapen S Semin Oncol; 2022 Apr; 49(2):170-177. PubMed ID: 35027218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]